DATA GRAPHICS | Deals
Data Bytes: Kymera- Sanofi deal is latest sign targeted degradation is growing up
July 10, 2020 1:08 AM UTC
Kymera and Sanofi’s deal brings the targeted protein degradation space its largest disclosed upfront and most advanced partnered asset to date.
The companies announced Thursday that Sanofi (Euronext:SAN; NASDAQ:SNY) will pay Kymera Therapeutics Inc. $150 million upfront for protein degrader therapies targeting IRAK4 with preclinical proof-of-concept against inflammatory diseases, plus an undisclosed earlier-stage program. Kymera is also eligible for more than $2 billion in development, regulatory and sales milestones and “significant royalty payments.” ...